SCHEMBL4513945

SCHEMBL4513945

COC(=O)c1cc(C(=O)c2c(C)c(-c3cccc(OCC(=O)NCCNC(=O)COc4cccc(-c5c(C)c(C(=O)c6ccc(N)c(C(=O)OC)c6)c6ccccn56)c4)c3)n3ccccc23)ccc1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 11/20 0.41
MAPT P10636 10/20 0.41
MEN1 O00255 9/20 0.41
ALDH1A1 P00352 8/20 0.41
LMNA P02545 4/20 0.41
PPARG P37231 4/20 0.41
NCOR2 Q9Y618 4/20 0.41
TDP1 Q9NUW8 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
GPR55 Q9Y2T6 1/20 0.41
KDM4E B2RXH2 4/20 0.40
PABPC1 P11940 2/20 0.40
HTT P42858 2/20 0.40
SAE1 Q9UBE0 2/20 0.40
UBA2 Q9UBT2 2/20 0.40
APAF1 O14727 1/20 0.40
G6PD P11413 1/20 0.40
CACNA1B Q00975 1/20 0.40
APBA1 Q02410 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4496163 0.93 KMT2A (0.42) KMT2AMAPTMEN1ALDH1A1LMNA
SCHEMBL1573418 0.89 KMT2A (0.41) KMT2AMAPTMEN1ALDH1A1LMNA
SCHEMBL4502205 0.85 MAPT (0.39) KMT2AMAPTMEN1ALDH1A1LMNA
SCHEMBL1572827 0.81 MEN1 (0.42) KMT2AMAPTMEN1ALDH1A1LMNA
SCHEMBL4509038 0.79 ALDH1A1 (0.40) KMT2AMAPTMEN1ALDH1A1LMNA
SCHEMBL4500632 0.79 ALDH1A1 (0.40) KMT2AMAPTMEN1ALDH1A1LMNA
SCHEMBL4508199 0.79 MAPT (0.43) KMT2AMAPTMEN1ALDH1A1LMNA
SCHEMBL4496158 0.79 KMT2A (0.40) KMT2AMAPTMEN1ALDH1A1LMNA
SCHEMBL4509501 0.78 KMT2A (0.41) KMT2AMAPTMEN1ALDH1A1LMNA
SCHEMBL1573410 0.78 ALDH1A1 (0.42) KMT2AMAPTMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 US disclosed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS FGF2, FGFR1, FGF1 KMT2A 3395/4885MAPT 3588/4885MEN1 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.